These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 34294370)
21. Implications for eicosapentaenoic acid- and docosahexaenoic acid-derived resolvins as therapeutics for arthritis. Souza PR; Norling LV Eur J Pharmacol; 2016 Aug; 785():165-173. PubMed ID: 26165764 [TBL] [Abstract][Full Text] [Related]
22. Ketamine: A tale of two enantiomers. Jelen LA; Young AH; Stone JM J Psychopharmacol; 2021 Feb; 35(2):109-123. PubMed ID: 33155503 [TBL] [Abstract][Full Text] [Related]
23. A hypothesis of monoamine (5-HT) - Glutamate/GABA long neural circuit: Aiming for fast-onset antidepressant discovery. Li YF Pharmacol Ther; 2020 Apr; 208():107494. PubMed ID: 31991195 [TBL] [Abstract][Full Text] [Related]
24. Eicosapentaenoic and docosahexaenoic acids have different effects on peripheral phospholipase A2 gene expressions in acute depressed patients. Su KP; Yang HT; Chang JP; Shih YH; Guu TW; Kumaran SS; Gałecki P; Walczewska A; Pariante CM Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jan; 80(Pt C):227-233. PubMed ID: 28648567 [TBL] [Abstract][Full Text] [Related]
25. Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites. Yang C; Yang J; Luo A; Hashimoto K Transl Psychiatry; 2019 Nov; 9(1):280. PubMed ID: 31699965 [TBL] [Abstract][Full Text] [Related]
26. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective. Hashimoto K Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725 [TBL] [Abstract][Full Text] [Related]
27. Arketamine, a new rapid-acting antidepressant: A historical review and future directions. Zhang JC; Yao W; Hashimoto K Neuropharmacology; 2022 Nov; 218():109219. PubMed ID: 35977629 [TBL] [Abstract][Full Text] [Related]
29. Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Mocking RJ; Harmsen I; Assies J; Koeter MW; Ruhé HG; Schene AH Transl Psychiatry; 2016 Mar; 6(3):e756. PubMed ID: 26978738 [TBL] [Abstract][Full Text] [Related]
30. International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder. Guu TW; Mischoulon D; Sarris J; Hibbeln J; McNamara RK; Hamazaki K; Freeman MP; Maes M; Matsuoka YJ; Belmaker RH; Jacka F; Pariante C; Berk M; Marx W; Su KP Psychother Psychosom; 2019; 88(5):263-273. PubMed ID: 31480057 [TBL] [Abstract][Full Text] [Related]
31. Do the dissociative side effects of ketamine mediate its antidepressant effects? Luckenbaugh DA; Niciu MJ; Ionescu DF; Nolan NM; Richards EM; Brutsche NE; Guevara S; Zarate CA J Affect Disord; 2014 Apr; 159():56-61. PubMed ID: 24679390 [TBL] [Abstract][Full Text] [Related]
32. Effects of prenatal n-3 fatty acid supplementation on offspring resolvins at birth and 12 years of age: a double-blind, randomised controlled clinical trial. See VHL; Mas E; Prescott SL; Beilin LJ; Burrows S; Barden AE; Huang RC; Mori TA Br J Nutr; 2017 Dec; 118(11):971-980. PubMed ID: 29173199 [TBL] [Abstract][Full Text] [Related]
33. The role of mTOR in depression and antidepressant responses. Abelaira HM; Réus GZ; Neotti MV; Quevedo J Life Sci; 2014 Apr; 101(1-2):10-4. PubMed ID: 24582593 [TBL] [Abstract][Full Text] [Related]
34. GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Liu RJ; Fuchikami M; Dwyer JM; Lepack AE; Duman RS; Aghajanian GK Neuropsychopharmacology; 2013 Oct; 38(11):2268-77. PubMed ID: 23680942 [TBL] [Abstract][Full Text] [Related]
35. Resolvins as proresolving inflammatory mediators in cardiovascular disease. Capó X; Martorell M; Busquets-Cortés C; Tejada S; Tur JA; Pons A; Sureda A Eur J Med Chem; 2018 Jun; 153():123-130. PubMed ID: 28732558 [TBL] [Abstract][Full Text] [Related]
36. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. Serhan CN; Gotlinger K; Hong S; Arita M Prostaglandins Other Lipid Mediat; 2004 Apr; 73(3-4):155-72. PubMed ID: 15290791 [TBL] [Abstract][Full Text] [Related]
37. Ketamine and its metabolites: Potential as novel treatments for depression. Zhang K; Yao Y; Hashimoto K Neuropharmacology; 2023 Jan; 222():109305. PubMed ID: 36354092 [TBL] [Abstract][Full Text] [Related]